Baerveldt glaucoma implant with Supramid© ripcord stent in neovascular glaucoma: a case series

作     者：Yuen Keat Gan Shiivaa Manjare Birapadian Muhammad Irfan Abdul Jalal Norshamsiah Md Din 

作者机构：Department of OphthalmologyFaculty of MedicineUniversiti Kebangsaan MalaysiaKuala Lumpur 56000Malaysia UKM Molecular Biology InstituteUniversiti Kebangsaan MalaysiaKuala Lumpur 56000Malaysia Hospital Canselor Tuanku MuhrizJalan Yaacob LatifBandar Tun RazakKuala Lumpur 56000Malaysia 

出 版 物：《International Journal of Ophthalmology(English edition)》 (国际眼科杂志（英文版）)

年 卷 期：2024年第17卷第2期

页      面：265-271页

核心收录：

学科分类：1002[医学-临床医学] 100212[医学-眼科学] 10[医学] 

主　　题：neovascular glaucoma Supramid ripcord stent Baerveldt glaucoma implant 

摘      要：AIM:To report the outcome of Baerveldt glaucoma implant(BGI)with Supramid©ripcord use in neovascular glaucoma(NVG).METHODS:We retrospectively evaluated the surgical outcome of the BGI with Supramid©3/0 ripcord stent in patients with *** tube ligation or venting slits were *** was removed after 3mo if the target intraocular pressure(IOP)was not *** success was defined as IOP≤21 mm Hg with(qualified success)or without IOP-lowering medications(complete success).RESULTS:Twenty-six eyes from 24 patients were included in the *** median duration of follow-up was 4[interquartile range(IQR)=1-5]y,ranging from 0.5 to *** decreased by a mean of 24.2 mm Hg(59.7%);from a mean of 40.5±12.6 mm Hg at baseline to 16.3±11.9 mm Hg,P≤*** number of glaucoma medications reduced from a median of 5(IQR=5-6)to 1(IQR=0-2,P≤0.001)at the final *** success rates were 88.0%at 1y,34.8%at 3y,66.7%at 4y,and 50%at *** phase(HP)in the first 3mo occurred in 15/26 eyes(57.7%)with a mean IOP of 31.1 mm ***:BGI with Supramid©ripcord stent gives close to 90%of the overall survival rate at the final follow-up without significant early ***,early HP is still a challenge.